Science laboratory test tubes, laboratory equipment

Our Work

Latham & Watkins Advises Octagon Therapeutics’ Research Alliance With Novo Nordisk

September 22, 2022

Firm represents the biopharmaceutical company in multi-year deal focused on inflammatory disease research.

Octagon Therapeutics, a preclinical-stage biopharmaceutical company developing targeted medicines for autoimmune disease, has announced the initiation of a research collaboration with Novo Nordisk focused on inflammatory disease. This multi-year relationship will apply Octagon's functional target discovery approach and novel chemistry strategy in disease areas in which Novo Nordisk has specific expertise.

Latham & Watkins LLP represents Octagon Therapeutics in the deal with a healthcare and life sciences team led by Bay Area partner Jekkie Kim.

Endnotes

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.